Replimune Group (REPL) Nosedives 39% as FDA Approval for Melanoma Treatment 'Uncertain'
Replimune extended losses to a second consecutive day on Thursday, slashing 39.40 percent to close at $3.46 apiece after failing to clear regulatory challenges for its treatment candidate for melanoma...